Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

OCREVUS ZUNOVO

OCRELIZUMAB AND HYALURONIDASE-OCSQ

Standard Dose
40MG;1000UNITS PER ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OCREVUS ZUNOVO is listed in Drugs@FDA under application 761371 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OCRELIZUMAB AND HYALURONIDASE-OCSQ Form and strength INJECTABLE;INJECTION - 40MG;1000UNITS PER ML Sponsor GENENTECH INC Submission history Latest submission status date: 2025-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview OCREVUS ZUNOVO is listed in Drugs@FDA under application 761371 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient OCRELIZUMAB AND HYALURONIDASE-OCSQ Form and strength INJECTABLE;INJECTION - 40MG;1000UNITS PER ML Sponsor GENENTECH INC Submission history Latest submission status date: 2025-08-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.